Cremophor is an emulsifying agent for the pharmaceuticals, cosmetics and feedstuffs industries; used in aqueous preparations of hydrophobic substances, e.g. fat-soluble vitamins and essential oils.
There is substantial interest regarding the understanding and designing of nanoengineered bacteria to combat various fatal cancerous diseases.
One of most potent drugs for treatment of glioblastoma, the most deadly type of brain tumor, can't be used in patients because of two problems. First, it can't reach its target because it's blocked by the blood-brain barrier, a microscopic structure that protects the brain from toxins in the blood. And the conventional formulation for this drug is toxic to the brain.
Oasmia Pharmaceutical AB, developer of a new generation of drugs within human and veterinary oncology, announced today the topline findings from a head-to-head comparison study of its lead human cancer product candidate Paclical and Celgene's Abraxane, which show similar pharmacokinetic (PK) profiles of the two products. The study was conducted in women with metastatic breast cancer.
Sorrento Therapeutics, Inc. and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq) and IG-004 (TOCOSOL paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine and the European Technology Platform on Nanomedicine in Basel, Switzerland on June 23 - 26.
Sorrento Therapeutics, Inc. and IGDRASOL announced today that clinical data for CynviloqTM, a non-biologic nanoparticle formulation of paclitaxel, plus gemcitabine was published for the upcoming Annual Meeting of the American Society of Clinical Oncology.
Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th).
Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its development of Cynviloq (IG-001) at the annual meeting of the American Association for Cancer Research in Washington, DC (April 6th to 10th).
NeuroVive announces publication of the results of a Phase I clinical trial of lead product CicloMulsion in the scientific journal Clinical Drug Investigation. The paper highlights that the intravenous cyclosporine formulation CicloMulsion demonstrates bioequivalence and improved tolerability when compared with Sandimmune Injection.
A mixture of current drugs and carbon nanoparticles shows potential to enhance treatment for head-and-neck cancers, especially when combined with radiation therapy, according to new research by Rice University and the University of Texas MD Anderson Cancer Center.
NeuroVive Pharmaceutical and Hospices Civils de Lyon (HCL) today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction (the CIRCUS study). NeuroVive's advanced CicloMulsion(TM) cremophor-free IV cyclosporine formulation is used in this study of 1,000 patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction to examine cyclosporine's ability to protect cardiac tissue.
NeuroVive Pharmaceutical and Hospices Civils de Lyon today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction.
Abraxis BioScience, Inc. announced today that findings from their phase 3 randomized trial of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) plus carboplatin, showed a statistically significant 31 percent improvement in overall response rate when compared with Taxol (paclitaxel) injection plus carboplatin in the first-line treatment of patients with non-small cell lung cancer.
A chemotherapy drug that is supposed to help save cancer patients' lives, instead resulted in life-threatening and sometimes fatal allergic reactions.
The U.S. Food and Drug Administration has approved Ixempra (ixabepilone), a new anti-cancer treatment, for use in patients with metastatic or locally advanced breast cancer who have not responded to certain other cancer drugs.
The New York Times has examined efforts by the pharmaceutical company Abraxis BioScience to obtain FDA approval for its late-stage breast cancer drug Abraxane as a treatment for earlier-stage breast cancer.
Abraxane (paclitaxel protein-bound particles for injectable suspension), a next generation taxane, and the first in a new class of albumin-bound nanotechnology, was approved for the treatment of metastatic breast cancer.
A Lawrence company that uses patented technology created at the University of Kansas to improve the effectiveness of drugs has won a $100,000 National Institutes of Health grant to support further testing of the company's promising new cancer drug, Nanotax.